Section

Analysis

Interpretation of the industry — what regulatory moves, trial readouts, and corporate actions actually mean. Distinct from news reporting and from opinion.

ANALYSIS

Behavioral-health payments are changing. Care coordination is a different problem.

A cluster of Medicare and Medicaid payment changes is reshaping behavioral-health economics this year. None addresses the separate question a new study raises about care coordination: 30.6 percent of Dual-Eligible Special Needs Plan enrollees using behavioral-health services had their care paid for by both Medicare and Medicaid, a payment-source split the study's author says may expose patients to fragmentation risk, not a measured outcome of the research itself.

By Editorial Desk · Sep 19, 2026 · 10 min read

ANALYSIS

On July 1, Georgia quietly reset the machinery of its public mental health system.

The medical-cannabis expansion is the headline. The same day, separate bills reconstitute the state's community service boards, tighten facility staffing and workforce-data requirements, and add reporting duties for cannabis-certifying physicians. The plumbing changes will outlast the headline.

By Editorial Desk · Jun 16, 2026 · 6 min

ANALYSIS

Reading the Lykos CRL: what the published rejection letter actually says

On September 4, 2025, the FDA released the redacted Complete Response Letter to Lykos as part of a broader publication of 89 previously unpublished CRLs. The document is now public reading. The methodological concerns it documents are more specific than the press coverage suggested, and the implications for the field's subsequent programs are larger.

By Editorial Desk · Jun 8, 2026 · 9 min

MARKET ANALYSIS

The 2026 mental health milestones are real. The headlines about them are wrong.

Psilocybin cleared two Phase 3 trials, cannabis moved partway to Schedule III, a new antipsychotic mechanism reached market, and telehealth kept scaling. In each vertical, the mechanism is narrower than the coverage.

By Editorial Desk · May 30, 2026 · 8 min

Analysis · Cannabis

Cannabis rescheduling: what an actual schedule III decision changes for operators

Most coverage of rescheduling fixates on 280E tax relief. The bigger story is what happens to research registration, FDA pathway access, and the M&A market for MSOs that have been frozen out of institutional capital for a decade.

By Editorial Desk · May 26, 2026 · 8 min

ANALYSIS · PHARMA

Sage's zuranolone disappointment ended in a Supernus acquisition. The structural problem with PPD-only labels remains.

When the FDA approved zuranolone for postpartum depression but rejected it for major depressive disorder, it built a commercial trap Sage could not escape independently. Supernus completed its acquisition of the company on July 31, 2025. The lesson about narrow psychiatric labels generalizes regardless.

By Editorial Desk · May 25, 2026 · 6 min

Analysis · Digital health

Hims, Talkspace, and the coming reckoning on telehealth psychiatry margins

Direct-to-consumer mental health platforms built businesses on the difference between cash-pay convenience and insurance reimbursement complexity. That gap is closing, not because of a regulatory clampdown that never happened, but because of the reimbursement side alone, and because the insurance-credentialed marketplaces that were supposed to be the beneficiaries are consolidating and straining under the same payer pressure.

By Editorial Desk · May 24, 2026 · 7 min